Chemistry:AFM-30a
From HandWiki
AFM-30a is an experimental drug which was the first selective inhibitor to be developed of the enzyme peptidylarginine deiminase 2 (PAD2). It has been used to investigate the role of PAD2 in various inflammatory conditions and development of cancers. It was found to be active against pulmonary fibrosis in a mouse model.[1][2][3][4][5]
See also
- BB-Cl-Amidine
- GSK484
- JBI-589
References
- ↑ "Development of a Selective Inhibitor of Protein Arginine Deiminase 2". Journal of Medicinal Chemistry 60 (7): 3198–3211. April 2017. doi:10.1021/acs.jmedchem.7b00274. PMID 28328217.
- ↑ "Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4". Frontiers in Immunology 12: 716250. 2021. doi:10.3389/fimmu.2021.716250. PMID 34737738.
- ↑ "Peptidylarginine deiminase (PAD): A promising target for chronic diseases treatment". International Journal of Biological Macromolecules 278 (Pt 3): 134576. October 2024. doi:10.1016/j.ijbiomac.2024.134576. PMID 39127273.
- ↑ "The vacuolar anti-Pseudomonal activity of neutrophil primary granule peptidyl-arginine deiminase enzymes". Frontiers in Immunology 15: 1452393. 2024. doi:10.3389/fimmu.2024.1452393. PMID 39493757.
- ↑ "[The effects and mechanisms of PAD2 inhibitor AFM-30a attenuates pulmonary fibrosis in silicotic mice]". Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi = Zhonghua Laodong Weisheng Zhiyebing Zazhi = Chinese Journal of Industrial Hygiene and Occupational Diseases 43 (1): 1–13. January 2025. doi:10.3760/cma.j.cn121094-20240102-00001. PMID 39909591.
 |  |
